GemVax&KAEL Co.,Ltd. (KOSDAQ:082270)

GemVax&KAEL Statistics

Total Valuation

GemVax&KAEL has a market cap or net worth of KRW 1.39 trillion. The enterprise value is 1.44 trillion.

Market Cap	1.39T
Enterprise Value	1.44T

Important Dates

The last earnings date was Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

GemVax&KAEL has 42.08 million shares outstanding. The number of shares has increased by 1.50% in one year.

Current Share Class	42.08M
Shares Outstanding	42.08M
Shares Change (YoY)	+1.50%
Shares Change (QoQ)	+3.25%
Owned by Insiders (%)	2.43%
Owned by Institutions (%)	4.41%
Float	30.80M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	18.86
PB Ratio	27.60
P/TBV Ratio	29.21
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-24.10
EV / Sales	19.54
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-78.63

Financial Position

The company has a current ratio of 0.51, with a Debt / Equity ratio of 1.40.

Current Ratio	0.51
Quick Ratio	0.37
Debt / Equity	1.40
Debt / EBITDA	n/a
Debt / FCF	-3.85
Interest Coverage	-1.92

Financial Efficiency

Return on equity (ROE) is -95.34% and return on invested capital (ROIC) is -6.27%.

Return on Equity (ROE)	-95.34%
Return on Assets (ROA)	-5.01%
Return on Invested Capital (ROIC)	-6.27%
Return on Capital Employed (ROCE)	-13.93%
Revenue Per Employee	404.62M
Profits Per Employee	-328.11M
Employee Count	182
Asset Turnover	0.49
Inventory Turnover	5.40

Taxes

Income Tax	-670.13M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +103.96% in the last 52 weeks. The beta is 0.98, so GemVax&KAEL's price volatility has been similar to the market average.

Beta (5Y)	0.98
52-Week Price Change	+103.96%
50-Day Moving Average	45,889.00
200-Day Moving Average	45,356.25
Relative Strength Index (RSI)	36.20
Average Volume (20 Days)	527,429

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GemVax&KAEL had revenue of KRW 73.64 billion and -59.72 billion in losses. Loss per share was -1,469.24.

Revenue	73.64B
Gross Profit	25.74B
Operating Income	-12.10B
Pretax Income	-60.39B
Net Income	-59.72B
EBITDA	-7.71B
EBIT	-12.10B
Loss Per Share	-1,469.24

Balance Sheet

The company has 19.72 billion in cash and 70.40 billion in debt, giving a net cash position of -50.68 billion or -1,204.46 per share.

Cash & Cash Equivalents	19.72B
Total Debt	70.40B
Net Cash	-50.68B
Net Cash Per Share	-1,204.46
Equity (Book Value)	50.30B
Book Value Per Share	1,157.78
Working Capital	-35.02B

Cash Flow

In the last 12 months, operating cash flow was -16.24 billion and capital expenditures -2.06 billion, giving a free cash flow of -18.30 billion.

Operating Cash Flow	-16.24B
Capital Expenditures	-2.06B
Free Cash Flow	-18.30B
FCF Per Share	-434.98

Margins

Gross margin is 34.95%, with operating and profit margins of -16.44% and -81.09%.

Gross Margin	34.95%
Operating Margin	-16.44%
Pretax Margin	-82.00%
Profit Margin	-81.09%
EBITDA Margin	-10.47%
EBIT Margin	-16.44%
FCF Margin	n/a

Dividends & Yields

GemVax&KAEL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.50%
Shareholder Yield	-1.50%
Earnings Yield	-4.30%
FCF Yield	-1.32%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GemVax&KAEL has an Altman Z-Score of 7.45 and a Piotroski F-Score of 3.

Altman Z-Score	7.45
Piotroski F-Score	3